JAK-IN-23

JAK-IN-23

• CAS Number: 3031837-35-8
• UNSPSC Description: JAK-IN-23 is an orally active double inhibitor of JAK/STAT and NF-κB. JAK-IN-23 can inhibit JAK1/2/3 with IC50 values of 8.9 nM, 15 nM and 46.2 nM, respectively. JAK-IN-23 has potent inhibitory activities against interferon-stimulated genes (ISG) and NF-κB pathways with IC50 values of 3.3 nM and 150.7 nM, respectively. JAK-IN-23 has great anti-inflammatory that decreases the release of various proinflammatory factors. JAK-IN-23 can be used for the research of inflammatory bowel disease (IBD)[1].
• Target Antigen: JAK; NF-κB; STAT; STING
• Type: Reference compound
• Related Pathways: Epigenetics;Immunology/Inflammation;JAK/STAT Signaling;NF-κB;Protein Tyrosine Kinase/RTK;Stem Cell/Wnt
• Applications: COVID-19-immunoregulation
• Field of Research: Inflammation/Immunology
• Assay Protocol: https://www.medchemexpress.com/jak-in-23.html
• Solubility: DMSO : 5 mg/mL (ultrasonic;warming;heat to 80°C)
• Smiles: OC1=C(Cl)C=C(C2=CC=C3N=CC(N=C(C)N4C5CCN(C)CC5)=C4C3=C2)C=C1Cl
• Molecular Weight: 441.35
• References & Citations: [1]Xuewu Liang, et al. Discovery of Novel Imidazo[4,5- c]quinoline Derivatives to Treat Inflammatory Bowel Disease (IBD) by Inhibiting Multiple Proinflammatory Signaling Pathways and Restoring Intestinal Homeostasis. J Med Chem. 2022 Sep 2.
• Shipping Conditions: Room Temperature
• Clinical Information: No Development Reported